Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela F Schwartz

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
BMC Medical Research Methodology|February 21, 2025
Comprehensive implementations of multiple imputation using retrieved dropouts for continuous endpointsShuai Wang, Pamela F Schwartz, James P Mancuso
Diabetes Technology & Therapeutics|August 31, 2011
Trough insulin levels in bronchoalveolar lavage following inhaled human insulin (Exubera) in patients with diabetes mellitusCarlos O Mendivil, John G Teeter, Gregory L Finch, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 19, 2019
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal AntibodiesEllen Q Wang, Jack F Bukowski, Carla Yunis, et al.
Current Medical Research and Opinion|October 3, 2008
Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapyWilliam T Cefalu, Nancy J V Bohannon, S Edwin Fineberg, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB studyJaren W Landen, Niels Andreasen, Carol L Cronenberger, et al.
Chest|September 25, 2007
Standardization of the single-breath diffusing capacity in a multicenter clinical trialRobert A Wise, John G Teeter, Robert L Jensen, et al.
Nature Medicine|June 27, 2025
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trialRussell J Butterfield, Perry B Shieh, Huihua Li, et al.
American Journal of Respiratory and Critical Care Medicine|May 10, 2008
Intersession variability in single-breath diffusing capacity in diabetics without overt lung diseaseMichael B Drummond, Pamela F Schwartz, William T Duggan, et al.
American Heart Journal|August 10, 2016
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes TrialsPaul M Ridker, Pierre Amarenco, Robert Brunell, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacyJaren W Landen, Sharon Cohen, Clare B Billing, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
BMC Medical Research Methodology|February 21, 2025
Comprehensive implementations of multiple imputation using retrieved dropouts for continuous endpointsShuai Wang, Pamela F Schwartz, James P Mancuso
Diabetes Technology & Therapeutics|August 31, 2011
Trough insulin levels in bronchoalveolar lavage following inhaled human insulin (Exubera) in patients with diabetes mellitusCarlos O Mendivil, John G Teeter, Gregory L Finch, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 19, 2019
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal AntibodiesEllen Q Wang, Jack F Bukowski, Carla Yunis, et al.
Current Medical Research and Opinion|October 3, 2008
Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapyWilliam T Cefalu, Nancy J V Bohannon, S Edwin Fineberg, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB studyJaren W Landen, Niels Andreasen, Carol L Cronenberger, et al.
Chest|September 25, 2007
Standardization of the single-breath diffusing capacity in a multicenter clinical trialRobert A Wise, John G Teeter, Robert L Jensen, et al.
Nature Medicine|June 27, 2025
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trialRussell J Butterfield, Perry B Shieh, Huihua Li, et al.
American Journal of Respiratory and Critical Care Medicine|May 10, 2008
Intersession variability in single-breath diffusing capacity in diabetics without overt lung diseaseMichael B Drummond, Pamela F Schwartz, William T Duggan, et al.
American Heart Journal|August 10, 2016
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes TrialsPaul M Ridker, Pierre Amarenco, Robert Brunell, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacyJaren W Landen, Sharon Cohen, Clare B Billing, et al.
Pageof 2